Complement receptors and B lymphocytes

Critical Reviews in Immunology

Volumn 24, Issue 6, 2004, Pages 465-478

  Villiers, Marie Bernadette ^a   Perrin Cocon, Laure ^a   Marche, Patrice N ^a   Villiers, Christian L ^a,b  

^a INSERM   (France)

^b CEA GRENOBLE   (France)

Author keywords

CD21; CD35; CD46; CD55; Immune response; Intracellular traffic

Indexed keywords

CELL SURFACE RECEPTOR; COMPLEMENT COMPONENT C3; COMPLEMENT RECEPTOR;

B LYMPHOCYTE; BINDING AFFINITY; CELL INTERACTION; CELL SURFACE; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; HOST RESISTANCE; HUMAN; IMMUNE RESPONSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION;

AMINO ACID SEQUENCE; B-LYMPHOCYTES; HUMANS; MOLECULAR SEQUENCE DATA; RECEPTORS, COMPLEMENT;

EID: 15444379312     PISSN: 10408401     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevImmunol.v24.i6.50     Document Type: Review

References (74)

1. Nussenzweig V, Green I. Lack of correlation between the net charge of antigen and antibodies in guinea pigs immunized with some charged antigens. J Immunol 1971; 106:1089-1094.
2. Pepys MB. Role of complement in induction of antibody production in vivo: effect of cobra factor and other C3-reactive agents on thymus-dependent and thymus-independent antibody responses. J Exp Med 1974; 140:126-145.
3. Villiers MB, Villiers CL, Laharie AM, Marche PN. Amplification of the antibody response by C3b complexed to antigen through an ester link. J Immunol 1999; 162:3647-3652.
4. Prodeus AP, Goerg S, Shen LM, Pozdnyakova OO, Chu L, Alicot EM, Goodnow CC, Carroll MC. A critical role for complement in maintenance of self-tolerance. Immunity 1998; 9:721-731.
5. Zhou W, Song L, Patel H, Li K, Farrar CA, Villiers M-B, Sacks SH. Endogenous C3 expresszion affects the potency of macrophages as stimulators of T cell alloreactivity. Mol Immunol 2004; 41:332.
6. Kirkitadze MD, Barlow PN. Structure and flexibility of the multiple domain proteins that regulate complement activation. Immunol Rev 2001; 180:146-161.
7. Smith BO, Mallin RL, Krych-Goldberg M, Wang X, Hauhart RE, Bromek K, Uhrin D, Atkinson JP, Barlow PN. Structure of the C3b binding site of CR1 (CD35), the immune adherence receptor. Cell 2002; 108:769-780.
8. Marie JC, Astier AL, Rivailler P, Rabourdin-Combe C, Wild TF, Horvat B. Linking innate and acquired immunity: divergent role of CD46 cytoplasmic domains in T cell induced inflammation. Nat Immunol 2002; 3:659-666.
9. Riley-Vargas RC, Gill DB, Kemper C, Liszewski MK, Atkinson JP. CD46: expanding beyond complement regulation. Trends Immunol 2004; 25:496-503.
10. Lukacik P, Roversi P, White J, Esser D, Smith GP, Billington J, Williams PA, Rudd PM, Wormald MR, Harvey DJ, Crispin MD, Radcliffe CM, Dwek RA, Evans DJ, Morgan BP, Smith RA, Lea SM. Complement regulation at the molecular level: the structure of decay-accelerating factor. Proc Natl Acad Sci USA 2004; 101:1279-1284.
11. Cherukuri A, Carter RH, Brooks S, Bornmann W, Finn R, Dowd CS, Pierce SK. B cell signaling is regulated by induced palmitoylation of CD81. J Biol Chem 2004; 279:31973-31982.
12. Cherukuri A, Cheng PC, Pierce SK. The role of the CD19/CD21 complex in B cell processing and presentation of complement-tagged antigens. J Immunol 2001; 167:163-172.
13. Gorelik L, Cutler AH, Thill G, Miklasz SD, Shea DE, Ambrose C, Bixler SA, Su L, Scott ML, Kalled SL. Cutting edge: BAFF regulates CD21/35 and CD23 expression independent of its B cell survival function. J Immunol 2004; 172:762-766.
14. Carter RH, Fearon DT. CD19: lowering the threshold for antigen receptor stimulation of B lymphocytes. Science 1992; 256:105-107.
15. Fearon DT, Carter RH. The CD19/CR2/TAPA-1 complex of B lymphocytes: linking natural to acquired immunity. Ann Rev Immunol 1995; 13:127-149.ÿ
16. Carter RH, Tuveson DA, Park DJ, Rhee SG, Fearon DT. The CD19 complex of B lymphocytes. Activation of phospholipase C by a protein tyrosine kinase-dependent pathway that can be enhanced by the membrane IgM complex. J Immunol 1991; 147:3663-3671.
17. Cherukuri A, Cheng PC, Sohn HW, Pierce SK. The CD19/CD21 complex functions to prolong B cell antigen receptor signaling from lipid rafts. Immunity 2001; 14:169-179.
18. Dempsey PW, Allison ME, Akkaraju S, Goodnow CC, Fearon DT. C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science 1996; 271:348-350.
19. Barel M, Le Romancer M, Frade R. Activation of the EBV/C3d receptor (CR2, CD21) on human B lymphocyte surface triggers tyrosine phosphorylation of the 95-kDa nucleolin and its interaction with phosphatidylinositol 3 kinase. J Immunol 2001; 166:3167-3173.
20. Barel M, Balbo M, Le Romancer M, Frade R. Activation of Epstein-Barr virus/C3d receptor (gp140, CR2, CD21) on human cell surface triggers pp60src and Akt-GSK3 activities upstream and downstream to PI 3-kinase, respectively. Eur J Immunol 2003; 33:2557-2566.
21. Thornton BP, Vetvicka V, Ross GD. Natural antibody and complement-mediated antigen processing and presentation by B lymphocytes. J Immunol 1994; 152:1727-1737.
22. Barrault DV, Knight AM. Distinct sequences in the cytoplasmic domain of complement receptor 2 are involved in antigen internalization and presentation. J Immunol 2004; 172:3509-3517.
23. Tuveson DA, Ahearn JM, Matsumoto AK, Fearon DT. Molecular interactions of complement receptors on B lymphocytes: a CR1/CR2 complex distinct from the CR2/CD19 complex. J Exp Med 1991; 173: 1083-1089.
24. Grattone ML, Villiers CL, Villiers MB, Drouet C, Marche PN. Co-operation between human CR1 (CD35) and CR2 (CD21) in internalization of their C3b and iC3b ligands by murine- transfected fibroblasts. Immunology 1999; 98:152-157.
25. Kozono Y, Abe R, Kozono H, Kelly RG, Azuma T, Holers VM. Cross-linking CD21/CD35 or CD19 increases both B7-1 and B7-2 expression on murine splenic B cells. J Immunol 1998; 160: 1565-1572.
26. Hivroz C, Fischer E, Kazatchkine MD, Grillot-Courvalin C. Differential effects of the stimulation of complement receptors CR1 (CD35) and CR2 (CD21) on cell proliferation and intracellular Ca2+ mobilization of chronic lymphocytic leukemia B cells. J Immunol 1991; 146:1766-1772.
27. Jozsi M, Prechl J, Bajtay Z, Erdei A. Complement receptor type 1 (CD35) mediates inhibitory signals in human B lymphocytes. J Immunol 2002; 168: 2782-2788.
28. Daha MR, Bloem AC, Ballieux RE. Immunoglobulin production by human peripheral lymphocytes induced by anti-C3 receptor antibodies. J Immunol 1984; 132:1197-1201.
29. Weiss L, Delfraissy JF, Vazquez A, Wallon C, Galanaud P, Kazatchkine MD. Monoclonal antibodies to the human C3b/C4b receptor (CR1) enhance specific B cell differentiation. J Immunol 1987; 138:2988-2993.
30. Kuraya M, Fujita T. Signal transduction via a protein associated with a glycosylphosphatidylinositol-anchored protein, decay-accelerating factor (DAF/CD55). Int Immunol 1998; 10:473-480.
31. Shenoy-Scaria AM, Kwong J, Fujita T, Olszowy MW, Shaw AS, Lublin DM. Signal transduction through decay-accelerating factor. Interaction of glycosylphosphatidylinositol anchor and protein tyrosine kinases p56lck and p59fyn 1. J Immunol 1992; 149:3535-3541.
32. Shibuya K, Abe T, Fujita T. Decay-accelerating factor functions as a signal transducing molecule for human monocytes. J Immunol 1992; 149:1758-1762.
33. Astier A, Trescol-Biemont MC, Azocar O, Lamouille B, Rabourdin-Combe C. Cutting edge: CD46, a new costimulatory molecule for T cells, that induces p120CBL and LAT phosphorylation. J Immunol 2000; 164:6091-6095.
34. Zaffran Y, Destaing O, Roux A, Ory S, Nheu T, Jurdic P, Rabourdin-Combe C, Astier AL. CD46/ CD3 costimulation induces morphological changes of human T cells and activation of Vav, Rac, and extracellular signal-regulated kinase mitogen-activated protein kinase. J Immunol 2001; 167:6780-6785.
35. Wang G, Liszewski MK, Chan AC, Atkinson JP. Membrane cofactor protein (MCP, CD46): isoform-specific tyrosine phosphorylation. J Immunol 2000; 164:1839-1846.
36. Gerlier D, Trescol-Biemont MC, Varior-Krishnan G, Naniche D, Fugier-Vivier I, Rabourdin-Combe C. Efficient major histocompatibility complex class II-restricted presentation of measles virus relies on hemagglutinin- mediated targeting to its cellular receptor human CD46 expressed by murine B cells. J Exp Med 1994; 179:353-358.
37. Rivailler P, Trescol-Biemont MC, Gimenez C, Rabourdin-Combe C, Horvat B. Enhanced MHC class II-restricted presentation of measles virus (MV) hemagglutinin in transgenic mice expressing human MV receptor CD46. Eur J Immunol 1998; 28:1301-1314.
38. Arvieux J, Yssel H, Colomb MG. Antigen-bound C3b and C4b enhance antigen-presenting cell function in activation of human T-cell clones. Immunology 1988; 65:229-235.
39. Jacquier-Sarlin MR, Gabert FM, Villiers MB, Colomb MG. Modulation of antigen processing and presentation by covalently linked complement C3b fragment. Immunology 1995; 84:164-170.
40. Pinet V, Vergelli M, Martin R, Bakke O, Long EO. Antigen presentation mediated by recycling of surface HLA- DR molecules. Nature 1995; 375:603-606.
41. Pinet VM, Long EO. Peptide loading onto recycling HLA-DR molecules occurs in early endosomes. Eur J Immunol 1998; 28:799-804.
42. Cheng PC, Steele CR, Gu L, Song W, Pierce SK. MHC class II antigen processing in B cells: accelerated intracellular targeting of antigens. J Immunol 1999; 162:7171-7180.
43. West MA, Lucocq JM, Watts C. Antigen processing and class II MHC peptide-loading compartments in human B-lymphoblastoid cells. Nature 1994; 369: 147-151.
44. Pieters J. MHC class II compartments: specialized organelles of the endocytic pathway in antigen presenting cells. Biol Chem 1997; 378:751-758.
45. Davidson HW, Reid PA, Lanzavecchia A, Watts C. Processed antigen binds to newly synthesized MHC class II molecules in antigen-specific B lymphocytes. Cell 1991; 67:105-116.
46. Hess MW, Schwendinger MG, Eskelinen EL, Pfaller K, Pavelka M, Dierich MP, Prodinger WM. Tracing uptake of C3dg-conjugated antigen into B cells via complement receptor type 2 (CR2, CD21). Blood 2000; 95:2617-2623.
47. Perrin-Cocon LA, Villiers CL, Salamero J, Gabert F, Marche PN. B cell receptors and complement receptors target the antigen to distinct intracellular compartments. J Immunol 2004; 172:3564-3572.
48. Nielsen CH, Leslie RG. Complement's participation in acquired immunity. J Leukoc Biol 2002; 72:249-261.
49. Pozdnyakova O, Guttormsen HK, Lalani FN, Carroll MC, Kasper DL. Impaired antibody response to group B streptococcal type III capsular polysaccharide in C3- and complement receptor 2-deficient mice. J Immunol 2003; 170:84-90.
50. Heyman B, Wiersma EJ, Kinoshita T. In vivo inhibition of the antibody response by a complement receptor-specific monoclonal antibody. J Exp Med 1990; 172:665-668.
51. Hebell T, Ahearn JM, Fearon DT. Suppression of the immune response by a soluble complement receptor of B lymphocytes. Science 1991; 254:102-105.
52. Santoro L, Drouet C, Reboul A, Mach JP, Colomb MG. Covalent binding of C3b to monoclonal antibodies selectively up-regulates heavy chain epitope recognition by T cells. Eur J Immunol 1994; 24:1620-1626.
53. Prechl J, Baiu DC, Horvath A, Erdei A. Modeling the presentation of C3d-coated antigen by B lymphocytes: enhancement by CR1/2-BCR co-ligation is selective for the co-ligating antigen. Int Immunol 2002; 14:241-247.
54. Mold C, Nemerow GR, Bradt BM, Cooper NR. CR2 is a complement activator and the covalent binding site for C3 during alternative pathway activation by Raji cells. J Immunol 1988; 140:1923-1929.
55. Marquait HV, Svehag SE, Leslie RG. CR2 is the primary acceptor site for C3 during alternative pathway activation of complement on human peripheral B lymphocytes. J Immunol 1994; 153:307-315.
56. Erdei A, Melchers F, Schulz T, Dierich M. The action of human C3 in soluble or cross-linked form with resting and activated murine B lymphocytes. Eur J Immunol 1985; 15:184-188.
57. Melchers F, Erdei A, Corbel C, Leptin M, Schulz T, Dierich MP. Cell cycle control of activated, synchronized murine B lymphocytes: roles of macrophages and complement C3. Mol Immunol 1986; 23:1173-1176.
58. Frade R, Crevon MC, Barel M, Vazquez A, Krikorian L, Charriaut C, Galanaud P. Enhancement of human B cell proliferation by an antibody to the C3d receptor, the gp 140 molecule. Eur J Immunol 1985; 15: 73-76.
59. Wilson BS, Platt JL, Kay NE. Monoclonal antibodies to the 140,000 mol wt glycoprotein of B lymphocyte membranes (CR2 receptor) initiates proliferation of B cells in vitro. Blood 1985; 66:824-829.
60. Kerekes K, Prechl J, Bajtay Z, Jozsi M, Erdei A. A further link between innate and adaptive immunity: C3 deposition on antigen-presenting cells enhances the proliferation of antigen-specific T cells. Int Immunol 1998; 10:1923-1930.
61. Anh-Tuan N, Falus A, Fust G, Meretey K, Hollan SR. Appearance of covalently bound antigen in immune complexes formed during the activation of complement. J Immunol Methods 1984; 75:257-263.
62. Rossbacher J, Shlomchik MJ. The B cell receptor itself can activate complement to provide the complement receptor 1/2 ligand required to enhance B cell immune responses in vivo. J Exp Med 2003; 198:591-602.
63. Ross TM, Xu Y, Bright RA, Robinson HL. C3d enhancement of antibodies to hemagglutinin accelerates protection against influenza virus challenge. Nat Immunol 2000; 1:127-131.
64. Villiers MB, Villiers CL, Jacquier-Sarlin MR, Gabert FM, Journet AM, Colomb MG. Covalent binding of C3b to tetanus toxin: influence on uptake/internalization of antigen by antigen-specific and non-specific B cells. Immunology 1996; 89:348-355.
65. Serra VA, Cretin F, Pepin E, Gabert FM, Marche PN. Complement C3b fragment covalently linked to tetanus toxin increases lysosomal sodium dodecyl sulfate-stable HLA-DR dimer production. Eur J Immunol 1997; 27:2673-2679.
66. Papamichail M, Gutierrez C, Embling P, Johnson P, Holborow EJ, Pepys MB. Complement dependence of localisation of aggregated IgG in germinal centres. Scand J Immunol 1975; 4:343-347.
67. Qin D, Wu J, Carroll MC, Burton GF, Szakal AK, Tew JG. Evidence for an important interaction between a complement-derived CD21 ligand on follicular dendritic cells and CD21 on B cells in the initiation of IgG responses. J Immunol 1998; 161: 4549-4554.
68. Lindorfer MA, Jinivizian HB, Foley PL, Kennedy AD, Solga MD, Taylor RP. B cell complement receptor 2 transfer reaction. J Immunol 2003; 170: 3671-3678.
69. Barrington RA, Pozdnyakova O, Zafari MR, Benjamin CD, Carroll MC. B lymphocyte memory: role of stromal cell complement and FcgammaRIIB receptors. J Exp Med 2002; 196:1189-1199.
70. Mongini PK, Jackson AE, Tolani S, Fattah RJ, Inman JK. Role of complement-binding CD21/CD19/CD81 in enhancing human B cell protection from Fas-mediated apoptosis. J Immunol 2003; 171:5244-5254.
71. Reid KB, Colomb M, Petty F, Loos M. Complement component Cl and the collectins: first-line defense molecules in innate and acquired immunity. Trends Immunol 2002; 23:115-117.
72. Cattaneo R. Four viruses, two bacteria, and one receptor: membrane cofactor protein (CD46) as pathogens' magnet. J Virol 2004; 78:4385-4388.
73. Maurer K, Krey T, Moennig V, Thiel HJ, Rumenapf T. CD46 is a cellular receptor for bovine viral diarrhea virus. J Virol 2004; 78:1792-1799.
74. Lea S. Interactions of CD55 with non-complement ligands. Biochem Soc Trans 2002; 30:1014-1019.